Advertisement

Cyclosporine Injection

[12 May 2014]

Products Affected - Description

Cyclosporine 50 mg/mL solution for injection, Bedford
5 mL vial, 10 count (NDC 55390-0122-10)

Reason for the Shortage

  • Perrigo acquired Paddock Laboratories in July 2011. Perrigo discontinued cyclosporine injection in late-November, 2011.
  • Bedford has cyclosporine injection on shortage due to manufacturing delays. Bedford anticipates full availability of each presentation the company reintroduces to market.
  • Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.

Available Products

Sandimmune 50 mg/mL solution for injection, Novartis
5 mL ampule, 10 count (NDC 00078-0109-01)

Estimated Resupply Dates

Bedford has cyclosporine injection 5 mL vials on long term back order and the company cannot estimate a release date. Ben Venue manufactured cyclosporine injection for Bedford.

Related Shortages

Updated

May 12, 2014; February 14, 2014; November 15, 2013; September 16, 2013; August 5, 2013; June 27, 2013; May 30, 2013; March 29, 2013; January 30, 2013; November 12, 2012; September 19, 2012; August 1, 2012; June 18, 2012; June 5, 2012; May 1, 2012; March 20, 2012; February 8, 2012; January 4, 2012; December 6, 2011; November 21, 2011; October 26, 2011; September 20, 2011; June 7, 2010; June 2, 2010; May 24, 2010; April 30, 2010; April 5, 2010; March 16, 2010; March 1, 2010; February 5, 2010; January 12, 2009; December 15, 2008; December 1, 2008; November 3, 2008; October 15, 2008; September 9, 2008; August 18, 2008, University of Utah, Drug Information Service. Copyright 2014, University of Utah, Drug Information Service.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement